Samir Wadhawan
Bristol-Myers Squibb
8 Papers
18 Citations
Samir Wadhawan is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Medicine & Biobank. The author has an hindex of 6, co-authored 7 publications.
Chat about Author
Papers
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Bruno Sangro,Ignacio Melero,Samir Wadhawan,Richard S. Finn,Ghassan K. Abou-Alfa,Ann-Lii Cheng,Thomas Yau,Junji Furuse,Joong-Won Park,Zachary Boyd,Hao Tracy Tang,Yun Shen,Marina Tschaika,Jaclyn Neely,Anthony B. El-Khoueiry +14 more
TL;DR: Retrospective analyses suggest that anti-tumour immune response may play a role in the treatment benefit of nivolumab in HCC, and biomarkers of inflammation, and inflammatory gene signatures trended with improved survival and response.
353
Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank.
Joseph D. Szustakowski,Suganthi Balasubramanian,Erika Kvikstad,Shareef Khalid,Paola G. Bronson,Ariella Sasson,Emily Wong,Daren Liu,J. Wade Davis,Carolina Haefliger,A. Katrina Loomis,Rajesh Mikkilineni,Hyun Ji Noh,Samir Wadhawan,Xiaodong Bai,Alicia Hawes,Olga Krasheninina,Ricardo Ulloa,Alex Lopez,E. N. Smith,Jeffrey F. Waring,Christopher D. Whelan,Ellen A. Tsai,John D. Overton,William J. Salerno,Howard J. Jacob,Sándor Szalma,Heiko Runz,Gregory Hinkle,Paul Nioi,Slavé Petrovski,Melissa R. Miller,Aris Baras,Lyndon J. Mitnaul,Jeffrey G. Reid +34 more
TL;DR: The UK Biobank Exome Sequencing Consortium (UKB-ESC) as mentioned in this paper is a private-public partnership between the UK Biopartition and eight biopharmaceutical companies that will complete the sequencing of exomes for all ~500,000 UKB participants.
Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
Joseph D. Szustakowski,Suganthi Balasubramanian,Ariella Sasson,Shareef Khalid,Paola G. Bronson,Erika Kvikstad,Emily Wong,Daren Liu,J. Wade Davis,Carolina Haefliger,A. Katrina Loomis,Rajesh Mikkilineni,Hyun Ji Noh,Samir Wadhawan,Xiaodong Bai,Alicia Hawes,Olga Krasheninina,Ricardo Ulloa,Alex Lopez,E. N. Smith,Jeff Waring,Christopher D. Whelan,Ellen A. Tsai,John D. Overton,William J. Salerno,Howard Jacob,Sándor Szalma,Heiko Runz,Greg Hinkle,Paul Nioi,Slavé Petrovski,Melissa R. Miller,Aris Baras,Lyndon J. Mitnaul,Jeffrey G. Reid +34 more
TL;DR: Early results from the exome sequence data generated by the UKB-ESC for the first ~200,000 UKB subjects are described and the rationale for the use of human genetics in drug discovery as well as lessons learned are described.
SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH.
Yi Luo,Samir Wadhawan,Alex Greenfield,Benjamin E. Decato,Abdul M. Oseini,Rebecca Collen,Diane E. Shevell,John Ryan Thompson,Gabor Jarai,Edgar D. Charles,Arun J. Sanyal +10 more
- 20 Jan 2021
TL;DR: A SOMAscan proteomics‐based exploratory classifier for advanced fibrosis, consisting of biomarkers that reflect the complexity of NASH pathophysiology, demonstrated similar performance in independent validation cohorts and performed similarly or better than Fibrosis‐4 index, aspartate aminotransferase–to‐platelet ratio index, and NAFLD fibrosis score.
58
Na-V channel variants in patients with painful and nonpainful peripheral neuropathy
Samir Wadhawan,Saumya Pant,Ryan Golhar,Stefan Kirov,John Thompson,Leslie Jacobsen,Irfan Qureshi,Senda Ajroud-Driss,Roy Freeman,David M. Simpson,A. Gordon Smith,Ahmet Hoke,Linda J. Bristow +12 more
TL;DR: The results suggest that identification of a genetically defined subpopulation for testing of NaV1.7 inhibitors in patients with peripheral neuropathy is unlikely and that additional factors, beyond expression of previously reported disease “mutations,” are more important for the development of painful neuropathy than previously discussed.